Musculoskeletal Phase 3 Readout Calendar
Industry-sponsored musculoskeletal trials with primary completion in the next 12 months or last 12 months.
Data last updated September 20, 2026 · source: ClinicalTrials.gov
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 musculoskeletal trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Musculoskeletal landscape →
Recently read out & awaiting topline — Musculoskeletal
· 3Phase 3 musculoskeletal trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Taisho Pharmaceutical Indonesia | Counterpain PXM Versus Diclofenac Versus Piroxicam | Ankle Sprain +4 | Completed | Q1 2026 2026-02-12 | Completed · awaiting
Updated 6mo ago
| NCT07475663 |
| Amzell | A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms Asset: AMZ001 Diclofenac gel | Osteoarthritis of Knee +1 | Completed | Q4 2025 2025-12-22 | Completed · awaiting
Updated 8mo ago
| NCT06693648 |
| Laboratorios Silanes S.A. de C.V. | Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm Asset: Etoricoxib + Tizanidine fixed dose | Acute Low-back Pain +1 | Completed | Q3 2025 2025-09-26 | Completed · awaiting
Updated 8mo ago
| NCT06863662 |
Upcoming musculoskeletal readouts — next 12 months
· 16Industry Phase 3 musculoskeletal trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Chongqing Claruvis Pharmaceutical … | A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults Asset: Recombinant Botulinum Toxin Type A for injection (YY001) | Upper Limb Spasticity | Recruiting | Q3 2026 2026-09-30 (est.) | Estimated · aging
Updated 8mo ago
| NCT06783114 |
| Arthrosi Therapeutics | Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302) Asset: AR882 50 mg | Gout +3 | Completed | Q4 2026 2026-11 (est.) | Estimated · stale
Updated 17mo ago
| NCT06439602 |
| Saol Therapeutics Inc | Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain Asset: SL1002 | Osteoarthritis Knee Pain | Recruiting | Q4 2026 2026-11-30 (est.) | Estimated · fresh
Updated 6mo ago
| NCT07226258 |
| R-Bio | Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial Asset: JOINTSTEM | Knee Osteoarthritis | Active Not Recruiting | Q4 2026 2026-12-23 (est.) | Estimated · stale
Updated 38mo ago
| NCT04427930 |
| Nature Cell Co. Ltd. | A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis Asset: JointStem | Osteoarthritis, Knee | Active Not Recruiting | Q4 2026 2026-12-30 (est.) | Estimated · stale
Updated 14mo ago
| NCT04368806 |
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.